SERPINA1 and pulmonary emphysema: Patients with AATD are treated with supplementation of plasma-derived AAT: a randomized controlled phase II trial demonstrated that augmentation therapy with AAT 60 mg/kg per week over 24 months in patients with AATD (92 receiving the augmentation therapy and 85 treated with placebo) delayed onset and progression of emphysema.248